Q4 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Sep 28, 2026
Nanoviricides, Inc. (NNVC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q4 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $2.2 million. Free cash flow was -$2.1 million.
Revenue
$0
Net income
$-2.22M
-6.1% vs year-ago quarter
Operating cash flow
$-2.12M
-24.7% vs year-ago quarter
Free cash flow
$-2.12M
-23.9% vs year-ago quarter
EPS
$-0.10
+22.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
25.52M
+46.4% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NNVC (NYSE)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Shelton, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1379006
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$2.2M | -$2.0M | -$2.2M | -$1.8M | -$2.1M |
| Net income | -$2.2M | -$2.0M | -$2.2M | -$1.8M | -$2.1M |
| Diluted EPS | -$0.10 | -$0.09 | -$0.11 | -$0.10 | -$0.13 |
| Operating cash flow | -$2.1M | -$1.9M | -$2.0M | -$1.6M | -$1.7M |
| Free cash flow | -$2.1M | -$1.9M | -$2.0M | -$1.7M | -$1.7M |
| Total assets | $9.9M | $10.2M | $12.3M | $8.4M | $8.8M |
| Total liabilities | $1.2M | $1.1M | $1.2M | $1.2M | $1.3M |
| Stockholders' equity | $8.7M | $9.2M | $11.1M | $7.2M | $7.5M |
| Cash and investments | $2.8M | $3.2M | $5.2M | $1.1M | $1.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 29, 2026 | Sep 28, 2026 |
| 10-K | Annual report | Sep 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 30, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 17, 2026 | Jul 17, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 21, 2026 | May 20, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
May 20, 2026 | May 15, 2026 |
All 556 Nanoviricides, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.